Skip to content
Home/Companies/Biotech/ReViral

ReViral

Biotech·United Kingdom·Exited 2022·Held 7yr
Entry
2015
Hold
7yr
Exit
2022

Who owns ReViral?

ReViral is a British Biotech company, now owned by Pfizer, which acquired it in 2022 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 4 · 2013 · VC

Key facts

HQUnited Kingdom
SectorBiotech
Exit Type
Trade Sale
Buyer
Pfizer
Exit Year
2022

More from BioDiscovery 4

Other portfolio companies in the same fund.

Inotrem
Active
BiotechFrance
MedDay Pharmaceuticals
Exited 2021
BiotechFrance· 2016
Verona Pharma
Verona Pharma
Exited 2017
BiotechUK· 2016
Autonomic Technologies
Exited 2020
MedTechUS· 2015
to Unity HA
Gamamabs
Active
BiotechFrance· 2015
Sanifit
Exited 2021
BiotechSpain· 2015
to Vifor Pharma

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ReViral?

ReViral is now owned by Pfizer, which acquired it in 2022 from Andera Partners.

When did Pfizer acquire ReViral?

Pfizer acquired ReViral in 2022, buying from Andera Partners.

Who did ReViral sell to?

Andera Partners sold ReViral to Pfizer in 2022 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue